Biogen’s Spinraza Stays Ahead Of Novartis And Roche Challengers In SMA – For Now
Evrysdi Growing Fast
Biogen is hoping to stem the decline in its blockbuster’s revenues but Novartis’ Zolgensma and Roche’s Evrysdi look hard to stop.
You may also be interested in...
While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.